147 related articles for article (PubMed ID: 11254112)
1. Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3.
Peter I; Mezzacasa A; LeDonne P; Dummer R; Hemmi S
Melanoma Res; 2001 Feb; 11(1):21-30. PubMed ID: 11254112
[TBL] [Abstract][Full Text] [Related]
2. Cloning, expression and tissue distribution of the murine homologue of the melanocyte lineage-specific antigen gp100.
Schreurs MW; de Boer AJ; Schmidt A; Figdor CG; Adema GJ
Melanoma Res; 1997 Dec; 7(6):463-70. PubMed ID: 9464618
[TBL] [Abstract][Full Text] [Related]
3. Frequent downregulation of Fas (CD95) expression and function in melanoma.
Bullani RR; Wehrli P; Viard-Leveugle I; Rimoldi D; Cerottini JC; Saurat JH; Tschopp J; French LE
Melanoma Res; 2002 Jun; 12(3):263-70. PubMed ID: 12140383
[TBL] [Abstract][Full Text] [Related]
4. Impact of interferons on the expression of melanoma-associated antigens in melanoma short-term cell cultures.
Hofbauer GF; Geertsen R; Laine E; Burg G; Dummer R
Melanoma Res; 2001 Jun; 11(3):213-8. PubMed ID: 11468509
[TBL] [Abstract][Full Text] [Related]
5. In vitro comparison between mouse B16 and human melanoma cell lines of the expression of ICAM-1 induced by cytokines and/or hyperthermia.
Nakayama J; Guan XC; Nakashima M; Mashino T; Hori Y
J Dermatol; 1997 Jun; 24(6):351-60. PubMed ID: 9241963
[TBL] [Abstract][Full Text] [Related]
6. Modulation by retinoids of mRNA levels for nuclear retinoic acid receptors in murine melanoma cells.
Clifford JL; Petkovich M; Chambon P; Lotan R
Mol Endocrinol; 1990 Oct; 4(10):1546-55. PubMed ID: 2178220
[TBL] [Abstract][Full Text] [Related]
7. Effect of adriblastin on viability, cell cycle and apoptosis in B16 and cloudman s91 mouse melanoma cells in vitro.
Olszewska-Słonina D; Drewa T; Czajkowski R; Olszewski K
Acta Pol Pharm; 2004; 61(6):439-46. PubMed ID: 15794336
[TBL] [Abstract][Full Text] [Related]
8. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.
Böhm W; Thoma S; Leithäuser F; Möller P; Schirmbeck R; Reimann J
J Immunol; 1998 Jul; 161(2):897-908. PubMed ID: 9670968
[TBL] [Abstract][Full Text] [Related]
9. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
Bullock TN; Mullins DW; Colella TA; Engelhard VH
J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
[TBL] [Abstract][Full Text] [Related]
10. Molecular Cytogenetic Characterization of the Murine Melanoma Cell Lines S91 Clone M3 and B16-F1 with Variant B16-4A5.
Piaszinski K; Rincic M; Liehr T; Azawi S
Cytogenet Genome Res; 2021; 161(1-2):82-92. PubMed ID: 33596583
[TBL] [Abstract][Full Text] [Related]
11. Demonstration of B700 cross-reactive antigens on human and other animal melanomas.
Gersten DM; Hearing VJ
Pigment Cell Res; 1988; 1(6):434-8. PubMed ID: 3237611
[TBL] [Abstract][Full Text] [Related]
12. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
13. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
Dezfouli S; Hatzinisiriou I; Ralph SJ
Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
[TBL] [Abstract][Full Text] [Related]
14. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation and function of the Fas/Fas ligand system in human trophoblast cells.
Aschkenazi S; Straszewski S; Verwer KM; Foellmer H; Rutherford T; Mor G
Biol Reprod; 2002 Jun; 66(6):1853-61. PubMed ID: 12021072
[TBL] [Abstract][Full Text] [Related]
16. Tyrosinase expression and melanogenesis in melanotic and amelanotic B16 mouse melanoma cells.
Burchill SA; Bennett DC; Holmes A; Thody AJ
Pathobiology; 1991; 59(5):335-9. PubMed ID: 1910528
[TBL] [Abstract][Full Text] [Related]
17. Over-expression of MSG1 transcriptional co-activator increases melanin in B16 melanoma cells: a possible role for MSG1 in melanogenesis.
Nair SS; Chaubal VA; Shioda T; Coser KR; Mojamdar M
Pigment Cell Res; 2001 Jun; 14(3):206-9. PubMed ID: 11434569
[TBL] [Abstract][Full Text] [Related]
18. B16 and cloudman S91 mouse melanoma cells susceptibility to apoptosis after dacarbazine treatment.
Olszewska-Słonina DM; Styczyńisk J; Drewa TA; Olszewski KJ; Czajkowski R
Acta Pol Pharm; 2005; 62(6):473-83. PubMed ID: 16583988
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
[TBL] [Abstract][Full Text] [Related]
20. Serological characterization of a shared melanoma-associated antigen of mouse melanomas: relationship to the B700 glycoprotein.
DeLeo AB; Hearing VJ; Vieira WD; Law LW
Melanoma Res; 1991; 1(2):133-40. PubMed ID: 1668533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
